Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC

Fineline Cube Dec 29, 2025
Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Fineline Cube Dec 29, 2025
Company Drug

NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination

Fineline Cube Jun 5, 2025

Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)...

Company Deals

SciBrunch Therapeutics Secures RMB 200 Million in Angel Financing Round

Fineline Cube Jun 5, 2025

Shanghai-based SciBrunch Therapeutics, a developer of small molecule anti-tumor drugs, has reportedly secured over RMB...

Company Drug

JW Therapeutics’ Carteyva Approved by Macau Health Bureau

Fineline Cube Jun 5, 2025

JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...

Company Deals

Sichuan Kelun-Biotech Raises $250M in Hong Kong’s Largest Follow-On Offering

Fineline Cube Jun 5, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the successful placement of 5,918,000 new...

Company Deals

Easton Pharma’s Oxazepam Receives NMPA Approval and Partners with Nhwa

Fineline Cube Jun 5, 2025

Chengdu-based Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that its oxazepam has received marketing approval...

Company Drug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease

Fineline Cube Jun 4, 2025

France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD)...

Company Drug

Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial

Fineline Cube Jun 4, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the Phase III clinical study of its...

Company Deals Drug

Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products

Fineline Cube Jun 4, 2025

US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with...

Company Drug

CirCode Biomed’s Circular RNA Drug HM2002 Approved for US Clinical Trials

Fineline Cube Jun 4, 2025

China-based Shanghai CirCode Biomed Co. Ltd., a specialist in circular RNA therapies, announced that its...

Company Medical Device

Bio-heart Launches Iberis Renal Ablation System at OCC 2025

Fineline Cube Jun 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its...

Company Deals

BioAge Labs Partners with JiKang for APJ Agonist Nanobody License

Fineline Cube Jun 4, 2025

US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...

Company Drug

Bayer’s Nubeqa Gets FDA Approval for mHSPC Treatment

Fineline Cube Jun 4, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration...

Company Deals

Sainte Nutritional Files for IPO in Hong Kong as FSMP Pioneer

Fineline Cube Jun 4, 2025

Sainte Nutritional Inc., China’s leading provider of Food for Special Medical Purpose (FSMP), has filed...

Company Drug

Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented the results of the Phase III CAMPASS study...

Company Deals

Harbin Gloria Partners with Eisai to Promote Methycobal in China

Fineline Cube Jun 4, 2025

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has entered into a market promotion service...

Company Drug

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Jun 4, 2025

Beijing-based Lepu Medical Technology (SHE: 300003), a provider of cardiovascular disease solutions, announced that its...

Company Drug

JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025

Fineline Cube Jun 4, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...

Company Drug

Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC

Fineline Cube Jun 4, 2025

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...

Company Medical Device Policy / Regulatory

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years

Fineline Cube Jun 4, 2025

China Central Television (CCTV) reported that EU member states have voted under the International Procurement...

Company Drug

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for...

Posts pagination

1 … 85 86 87 … 601

Recent updates

  • Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC
  • UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio
  • Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug
  • Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency
  • J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC

Company Medical Device

UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio

Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.